

SIROMOUNT


Sirolimus Eluting Coronary Stent System

SIROMOUNT

Sirolimus Eluting Coronary Stent System


UNIQUE FEATURES OF SIROMOUNT STENT

The next generation Ultra Thin Low Injury DES design, engineered to deliver Safety & Efficacy, with the proven efficacy of Sirolimus Drug, fully biodegradable polymers and Proprietary Electro-Polish CoCr platform.



ULTRA THIN STRUT THICKNESS OF SIROMOUNT STENT

Ultra thin strut thickness increases flexibility, reduces stent profile, improves trackability and easy access of complex lesion sites. It reduces stent-induced arterial injury and inflammation and facilitate faster endothelialization



Strut shape and thickness are for graphical representation purpose - not to scale

STRUT THICKNESS & STRUT WIDTH

Width > Thickness $= \uparrow$ Radial Strength

Engineering beam strength equation demonstrates that a 30% increase in width would result in a 2x increase in resistance.



% Change in Resistance

220%

Strut Width as a Percentage of Strut Thickness

SIROMOUNT


Sirolimus Eluting Coronary Stent System

OVER EXPANSION

No Structural deformation on over expansion (upto 5.00 mm) of the SIROMOUNT Stent Platform shows high resistance against arterial pressure and radial force.



DRUG RELEASE KINETICS



SIROMOUNT has proven drug release kinetics.
Initial burst release of Sirolimus followed by sustained release upto 40 days results in optimum intake of the drug and faster endothelialization.

EXCEPTIONAL SAFETY OF SIROMOUNT STENT

Late Lumen Loss In segment @ 6 m FUP 0.14 mm

Late Lumen Loss In stent @ 6 m FUP 0.10 mm

MACE @ 12m FUP 1.71% Cardiac death @ 12m FUP 0.57% TLR @ 12m FUP 1.14% 100% Procedural Success

COMPARISON BETWEEN SES PMS AND OTHER DES

| Stent Name | Mace | Late loss (mm) | Cardiac death | TLR |
|---|-------|--------------------|---------------|-------|
| SES PMS (6 month) (n=200) | 1.50% | 0.10 (at 6 month) | 0.50% | 1.00% |
| SES PMS (1 year) (n=175) | 1.71% | 0.10 (at 6 month) | 0.57% | 1.14% |
| Xience V, spirit II (n=223) (1 year) | 2.7% | 0.19 (at 6 months) | 0% | 1.8% |
| Xience V, spirit II (n=223) (2 year) | 6.4% | 0.19 (at 6 months) | 0.5% | 3.7% |
| Endeavour resolute (n=130) (1 year) | 8.5% | 0.22 (at 9 months) | 0.80% | 0.8% |
| Biomatrix (80 biomatrix subjects) (6 month) | 3.8% | 0.19 (at 6 months) | 0% | 1.3% |
| Biomatrix (80 biomatrix subjects) (1 year) | 5.1% | 0.19 (at 6 months) | NA | 0.8% |
| Biomime (n=242) (1 year) | 5.7% | 0.15 (at 8 months) | 0.50% | 4.7% |

| Available Stent Length (mm) | 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 50, 52 |
|-------------------------------|--|
| Available Stent Diameter (mm) | 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 3.75, 4.00, 4.50 |
| Models | 6 Cell design: 2.00, 2.25, 2.50, 2.75, 3.00 mm vessel wall |
| | 8 Cell design: 3.50, 3.75, 4.00, 4.50 mm vessel wall |
| Stent Material | A medical grade L605 Cobalt Chromium alloy |
| Design | Uniform sinusoidal cell design |
| Stent Strut thickness | 65 μm |
| Drug | Sirolimus |
| Drug Dose | 1.33 μg/mm² |
| Polymers | Biodegradable Polymer based matrix |

ORDERING INFORMATION

| Stent | | Stent length (mm) | | | | | | | | | | | |
|------------------|----------|-------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| diameter (mm) | 8 | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 50 | 52 |
| 2.00 | SM2.0008 | SM2.0012 | SM2.0016 | SM2.0020 | SM2.0024 | SM2.0028 | SM2.0032 | SM2.0036 | SM2.0040 | SM2.0044 | SM2.0048 | SM2.0050 | SM2.0052 |
| 2.25 | SM2.2508 | SM2.2512 | SM2.2516 | SM2.2520 | SM2.2524 | SM2.2528 | SM2.2532 | SM2.2536 | SM2.2540 | SM2.2544 | SM2.2548 | SM2.2550 | SM2.2552 |
| 2.50 | SM2.5008 | SM2.5012 | SM2.5016 | SM2.5020 | SM2.5024 | SM2.5028 | SM2.5032 | SM2.5036 | SM2.5040 | SM2.5044 | SM2.5048 | SM2.5050 | SM2.5052 |
| 2.75 | SM2.7508 | SM2.7512 | SM2.7516 | SM2.7520 | SM2.7524 | SM2.7528 | SM2.7532 | SM2.7536 | SM2.7540 | SM2.7544 | SM2.7548 | SM2.7550 | SM2.7552 |
| 3.00 | SM3.0008 | SM3.0012 | SM3.0016 | SM3.0020 | SM3.0024 | SM3.0028 | SM3.0032 | SM3.0036 | SM3.0040 | SM3.0044 | SM3.0048 | SM3.0050 | SM3.0052 |
| 3.50 | SM3.5008 | SM3.5012 | SM3.5016 | SM3.5020 | SM3.5024 | SM3.5028 | SM3.5032 | SM3.5036 | SM3.5040 | SM3.5044 | SM3.5048 | SM3.5050 | SM3.5052 |
| 3.75 | SM3.7508 | SM3.7512 | SM3.7516 | SM3.7520 | SM3.7524 | SM3.7528 | SM3.7532 | SM3.7536 | SM3.7540 | SM3.7544 | SM3.7548 | SM3.7550 | SM3.7552 |
| 4.00 | SM4.0008 | SM4.0012 | SM4.0016 | SM4.0020 | SM4.0024 | SM4.0028 | SM4.0032 | SM4.0036 | SM4.0040 | SM4.0044 | SM4.0048 | SM4.0050 | SM4.0052 |
| 4.50 | SM4.5008 | SM4.5012 | SM4.5016 | SM4.5020 | SM4.5024 | SM4.5028 | SM4.5032 | SM4.5036 | SM4.5040 | SM4.5044 | SM4.5048 | SM4.5050 | SM4.5052 |



Registered Office & Factory Address:

Nano Therapeutics Pvt. Ltd.

Plot No. D-54/2, Hojiwala Industrial Estate, Road No. 23, Near Gate No. 3, Sachin Palsana Highway, Sachin, Surat - 394 230, Gujarat, India.

Tel: +91 88660 50898, +91 90330 50853

Email: info@nano-therapeutics.net Web: www.nano-therapeutics.net

Customer Care Helpline No: 1800 891 9097

Customer Care Email:

customercare@nano-therapeutics.net

EC REP

CMC Medical Devices & Drugs S.L.

C/Horacio Lengo Nº 18, CP 29006, Malága, Spain,

Tel: +34 951 214 054 Fax: +34 952 330 100

Email: info@cmcmedicaldevices.com

Note: SIROMOUNT is a trademark of Nano Therapeutics Pvt. Ltd. or its affiliates. Specifications are subject to revision, improvement & modifications (i) Orsiro (ii) Ultimaster (iii) Xience V (iv) Endeavour Resolute (v) Biomatrix & (vi) Biomime are the registered Trademarks of Biotronik SE, Terumo Corporation, Abbott Group of Companies, Medtronic Inc. or its affiliates, Biosensors International & Meril Life Sciences respectively. Source: The source of information is based on the product brochures/catalogue of respective brands.